M/s. Saffron Media Private Limited has been arrayed as Defendant No.5 in the subject suit, together with its Editor-in-chief (Defendant No.6) and a reported (Defendant No.7) in respect of an article titled Karnataka DC to examine issue of adulterated curcumin sale by Bayir as Sami Labs takes legal action published on our website, www.pharmabiz.com on June 5, 2015. We have been served with the papers in the subject suit and we understand that the proceedings have been initiated in light of certain defamatory articles published against your company (including the abovementioned) for certain declaratory, injunctive and compensatory reliefs.

We have internally examined the issue and we are informed that the subject article was published by the Reported without ascertaining the factual correctness of the contents therein. To this end; we understand that the Reporter has already issued an unconditional apology in respect of the authorship.

In view of the unconditional apology tendered by our Reporter and upon examining the documents filed along with the Plaint in the subject suit, we regretfully understand that the publication among certain others, has indeed caused serious prejudice to your company and the management of M/s. Saffron Media Private Limited, hereby records its unconditionally apology for the publication of the article above mentioned. You will appreciate that M/s. Saffron Media Private Limited enjoys immense reputation as an unbiased trade reportage platform and therefore, as matter of policy we would not want to be associated with any reportage which is not entirely true. We would like to remain a neutral and fair platform for business information and in any event, would not want our professional ties to be jeopardized.

Accordingly, we hereby tender our unconditional apology for the publication of the aforementioned article. Please note that in compliance of the court order dated June 12, 2015, the said article stands removed from our website, www.pharmabiz.com.